AMAG Pharmaceuticals Stock Price - AMAG

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
AMAG Pharmaceuticals Inc AMAG NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.13 -1.39% 9.25 9.45 9.15 9.31 9.38 18:50:30
Bid Price Ask Price Spread Spread % News
9.10 9.76 0.66 6.76% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
5,371 487,134 $ 9.28 $ 4,521,954 878,555 6.81 - 19.44
Last Trade Time Type Quantity Stock Price Currency
16:41:06 2 $ 9.25 USD

AMAG Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 313.67M 33.91M $ -65.76M -1.92 -2.44 31.93M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

AMAG Pharmaceuticals News

Loading Messages....

Latest AMAG Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AMAG Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week9.9510.248.899.23796,918-0.70-7.04%
1 Month11.0513.538.3010.62998,433-1.80-16.29%
3 Months11.4813.538.3011.20873,116-2.23-19.43%
6 Months11.2613.536.8110.321,023,817-2.01-17.85%
1 Year17.7519.446.8111.86840,830-8.50-47.89%
3 Years29.8036.8256.8117.93908,161-20.55-68.96%
5 Years34.7177.736.8125.55895,022-25.46-73.35%

AMAG Pharmaceuticals Description

AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.